Sanofi (NASDAQ:SNY) Position Lessened by Bard Financial Services Inc.

Bard Financial Services Inc. lowered its position in Sanofi (NASDAQ:SNY) by 15.6% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 15,200 shares of the company’s stock after selling 2,800 shares during the quarter. Bard Financial Services Inc.’s holdings in Sanofi were worth $733,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. Stablepoint Partners LLC lifted its position in shares of Sanofi by 0.8% during the 3rd quarter. Stablepoint Partners LLC now owns 23,893 shares of the company’s stock worth $1,377,000 after buying an additional 189 shares during the period. PDS Planning Inc raised its stake in Sanofi by 3.1% during the third quarter. PDS Planning Inc now owns 6,643 shares of the company’s stock worth $383,000 after acquiring an additional 200 shares in the last quarter. Eagle Ridge Investment Management lifted its holdings in shares of Sanofi by 3.8% during the third quarter. Eagle Ridge Investment Management now owns 5,571 shares of the company’s stock valued at $321,000 after acquiring an additional 203 shares during the period. Financial Advocates Investment Management boosted its stake in shares of Sanofi by 3.4% in the 3rd quarter. Financial Advocates Investment Management now owns 6,327 shares of the company’s stock valued at $365,000 after purchasing an additional 206 shares in the last quarter. Finally, Angeles Investment Advisors LLC grew its holdings in shares of Sanofi by 1.9% in the 3rd quarter. Angeles Investment Advisors LLC now owns 11,323 shares of the company’s stock worth $653,000 after purchasing an additional 210 shares during the last quarter. 14.04% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

SNY has been the subject of several analyst reports. StockNews.com downgraded shares of Sanofi from a “buy” rating to a “hold” rating in a report on Thursday, December 12th. Citigroup raised Sanofi to a “strong-buy” rating in a report on Tuesday, September 17th. Two analysts have rated the stock with a hold rating, one has issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Sanofi presently has a consensus rating of “Moderate Buy” and a consensus price target of $57.50.

Sanofi Price Performance

SNY traded up $1.41 during midday trading on Monday, hitting $49.56. The company had a trading volume of 1,605,248 shares, compared to its average volume of 1,426,169. Sanofi has a twelve month low of $45.22 and a twelve month high of $58.97. The company has a market capitalization of $125.78 billion, a PE ratio of 25.29, a P/E/G ratio of 1.23 and a beta of 0.57. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.65 and a current ratio of 1.00. The firm’s 50-day simple moving average is $49.13 and its 200-day simple moving average is $52.07.

Sanofi (NASDAQ:SNY) last issued its quarterly earnings results on Friday, October 25th. The company reported $1.57 earnings per share for the quarter, beating analysts’ consensus estimates of $0.22 by $1.35. The business had revenue of $13.44 billion during the quarter, compared to analyst estimates of $16.59 billion. Sanofi had a net margin of 9.96% and a return on equity of 27.45%. Sanofi’s revenue for the quarter was up 12.3% compared to the same quarter last year. During the same quarter last year, the business posted $2.55 earnings per share. Equities research analysts predict that Sanofi will post 4.06 EPS for the current fiscal year.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.